Francis Medical Secures $80M in Series C Funding for Breakthrough Cancer Treatment Solutions

Francis Medical, Inc., a leading innovator in the field of minimally invasive treatments for prostate, kidney, and bladder cancer, has announced a significant funding milestone after successfully raising $80 million in its latest round of financing. Established in 2018 and headquartered in Maple Grove, Minnesota, Francis Medical is committed to advancing healthcare solutions through its groundbreaking convective thermal water vapor technology. The company's ongoing clinical trials aim to safely and effectively ablate cancerous prostate tissue, providing patients with less invasive and more manageable treatment options. The recent funding will be instrumental in accelerating the development of this promising technology, allowing Francis Medical to expand its clinical trials and navigate the regulatory approval pathway with greater speed. Moreover, this infusion of capital underscores the confidence investors have in the potential of Francis Medical to revolutionize cancer treatment and improve patient outcomes, particularly for those like Michael Hoey’s father, Francis, who suffered from the severe side effects of existing treatments. Since its inception, Francis Medical has successfully secured previous rounds of funding, including an $18 million Series A and a $55 million Series B financing; now, with this additional $80 million, they are poised to make significant strides in the fight against cancer. As the company continues its mission to develop innovative solutions and refine its technology, stakeholders and patients alike look forward to the potential breakthroughs on the horizon that could transform the landscape of cancer treatment.